J
Jaguar Health, Inc. (JAGX)
NCM – Real vaqt narxi. Valyuta: USD
3.25
-0.05 (-1.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.25
-0.05 (-1.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Jaguar Health, Inc. tijorat bosqichidagi farmatsevtika kompaniyasi bo'lib, oshqozon-ichak kasalliklari bilan og'rigan odamlar va hayvonlar uchun o'simlik asosidagi retsept bo'yicha dori vositalarini ishlab chiqishga qaratilgan. Kompaniya ikkita segment orqali ishlaydi: Hayvonlar salomatligi va Inson salomatligi. U sherik va ishlab chiqaruvchi hayvonlar uchun retsept bo'yicha va retseptsiz mahsulotlarni; hamda inson mahsulotlarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya Mytesi, tirikchilik davolash olayotgan kattalar orasida yuqumli bo'lmagan diareyani simptomatik davolash uchun sekretsiyaga qarshi diareyaga qarshi dori; va Canalevia-CA1, itlarda kimyoterapiya bilan bog'liq diareyani davolash uchun retsept bo'yicha dori vositasini taklif etadi. Shuningdek, u Crofelemer, sekretsiyaga qarshi diareyaga qarshi dori vositasini ishlab chiqmoqda, u saraton kasalligi bilan og'rigan kattalarda diareyani oldini olish bo'yicha III bosqich klinik sinovlarida; ingichka ichak sindromi bilan ichak etishmovchiligi va mikrovorusli inklyuziya kasalligi kabi kam uchraydigan/noyob kasalliklar uchun II bosqich klinik sinovlarida; diareya ustun bo'lgan tirnash xususiyati ichak sindromi; va idiopatik/funksional diareya uchun. Bundan tashqari, kompaniya Mytesi ni ishlab chiqmoqda, u saraton terapiyasi bilan bog'liq diareyani davolash uchun III bosqich klinik sinovlarida, shuningdek, tirnash xususiyati ichak sindromi uchun II bosqich klinik sinovlarida; va NP-300, o'rtacha va og'ir diareyani simptomatik davolash va davolash uchun I bosqich klinik sinovlarida bo'lgan ikkinchi avlod diareyaga qarshi dori vositasini ishlab chiqmoqda. Kompaniyaning shtab-kvartirasi San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Karen J. Brunke Ph.D. | Executive VP of Corporate & Business Development |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary |
| Mr. David Sesin Ph.D. | Chief Manufacturing Officer |
| Mr. Ian H. Wendt M.B.A. | Chief Commercial Officer |
| Mr. Jonathan S. Wolin C.P.A., J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & General Counsel |
| Mr. Peter Hodge | Senior Director of Investor Relations, Business Development & Special Events |
| Ms. Carol R. Lizak M.B.A. | Chief Financial Officer |
| Ms. Lisa A. Conte | Founder, CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | d55784d8k.htm |
| 2026-05-06 | DEFA14A | d104009ddefa14a.htm |
| 2026-05-04 | 8-K | d941132d8k.htm |
| 2026-04-30 | DEF 14A | d70657ddef14a.htm |
| 2026-04-27 | 8-K | d109088d8k.htm |
| 2026-04-21 | 8-K | d10648d8k.htm |
| 2026-04-20 | PRE 14A | d70657dpre14a.htm |
| 2026-04-09 | 8-K | d145473d8k.htm |
| 2026-04-07 | S-8 | d62839ds8.htm |
| 2026-04-01 | NT 10-K | d105764dnt10k.htm |